Respiratory Medicine
Sandoz Private Limited is involved in clinical research focused on asthma, with interest in therapies that address chronic airway inflammation and bronchoconstriction in adult patients.
- Asthma
- Adult respiratory care
- Airway symptom control
The company’s research activity in this area reflects attention to inhaled treatments used in routine management of obstructive airway disease.
Inhaled Combination Therapy
Its clinical interests include fixed-dose inhalation therapy combining an inhaled corticosteroid with a long-acting beta-agonist for maintenance treatment of asthma.
- Fluticasone furoate
- Vilanterol
- Inhaled corticosteroid and LABA combinations
This area supports evaluation of established respiratory treatment classes used to manage persistent symptoms and improve lung function.
Generic Respiratory Medicines
The sponsor also shows interest in generic medicine development within respiratory care, particularly products intended to match established branded inhalers used in asthma treatment.
- Therapeutic equivalence
- Bioequivalence
- Reference inhaler comparison
These activities are centered on respiratory products designed for clinical comparability in routine inhaled therapy.
Clinical Endpoint Evaluation
Clinical research activity includes assessment of efficacy and safety outcomes in adult participants with asthma, supporting evidence generation for inhaled respiratory treatments.
- Placebo-controlled assessment
- Adult asthma outcomes
- Safety evaluation
This focus aligns with therapeutic development in chronic respiratory disease management and comparative assessment of inhaled medicines.
